NASDAQ:RGLS - Regulus Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.28 -0.01 (-3.45 %) (As of 07/22/2018 06:42 AM ET)Previous Close$0.28Today's Range$0.2776 - $0.306652-Week Range$0.27 - $1.52Volume1.26 million shsAverage Volume1.12 million shsMarket Capitalization$29.21 millionP/E RatioN/ADividend YieldN/ABeta1.76 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California. Receive RGLS News and Ratings via Email Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:RGLS CUSIP75915K10 Webwww.regulusrx.com Phone858-202-6300 Debt Debt-to-Equity RatioN/A Current Ratio1.66 Quick Ratio1.66 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$70,000.00 Price / Sales417.28 Cash FlowN/A Price / CashN/A Book Value$0.34 per share Price / Book0.82 Profitability EPS (Most Recent Fiscal Year)($0.96) Net Income$-71,900,000.00 Net Margins-94,318.05% Return on Equity-214.48% Return on Assets-92.85% Miscellaneous Employees63 Outstanding Shares104,320,000Market Cap$29.21 Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions What is Regulus Therapeutics' stock symbol? Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS." How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc (NASDAQ:RGLS) released its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.15). The biopharmaceutical company earned $0.02 million during the quarter, compared to analysts' expectations of $0.02 million. Regulus Therapeutics had a negative net margin of 94,318.05% and a negative return on equity of 214.48%. View Regulus Therapeutics' Earnings History. When is Regulus Therapeutics' next earnings date? Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Regulus Therapeutics. What price target have analysts set for RGLS? 7 brokers have issued twelve-month price targets for Regulus Therapeutics' shares. Their predictions range from $0.50 to $6.00. On average, they expect Regulus Therapeutics' stock price to reach $2.10 in the next year. This suggests a possible upside of 650.0% from the stock's current price. View Analyst Ratings for Regulus Therapeutics. What is the consensus analysts' recommendation for Regulus Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 7 hold ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Regulus Therapeutics' key competitors? Some companies that are related to Regulus Therapeutics include Steadymed (STDY), Recro Pharma (REPH), Iterum Therapeutics (ITRM), Otonomy (OTIC), Affimed (AFMD), Alpine Immune Sciences (ALPN), Gemphire Therapeutics (GEMP), Aptevo Therapeutics (APVO), Infinity Pharmaceuticals (INFI), TapImmune Inc. common stock (TPIV), Aerpio Pharmaceuticals (ARPO), Oncolytics Biotech (ONCYF), GT Biopharma (GTBP), Trevena (TRVN) and Processa Pharmaceuticals (PCSA). Who are Regulus Therapeutics' key executives? Regulus Therapeutics' management team includes the folowing people: Mr. Joseph P. Hagan, Pres, CEO & Director (Age 49)Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)Dr. Timothy Michael Wright, Chief R&D Officer (Age 62)Dr. Mark Deeg, Chief Medical Officer (Age 58)Ms. Allison Wey, VP of Investor Relations & Corp. Communications Has Regulus Therapeutics been receiving favorable news coverage? Media stories about RGLS stock have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regulus Therapeutics earned a coverage optimism score of 0.08 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. How do I buy shares of Regulus Therapeutics? Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Regulus Therapeutics' stock price today? One share of RGLS stock can currently be purchased for approximately $0.28. How big of a company is Regulus Therapeutics? Regulus Therapeutics has a market capitalization of $30.46 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-71,900,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Regulus Therapeutics employs 63 workers across the globe. How can I contact Regulus Therapeutics? Regulus Therapeutics' mailing address is 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected] MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 363 (Vote Outperform)Underperform Votes: 181 (Vote Underperform)Total Votes: 544MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe RGLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?